Immunovant Insider Trades: COO Sell‑to‑Cover Signals Governance & Market Resilience
Immunovant’s latest sell‑to‑cover transaction shows routine tax compliance, yet the insider activity, regulatory scrutiny, and negative P/E hint at hidden risks and strategic opportunities for investors in the biotech sector.
4 minutes to read